Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial

阿利罗库单抗 医学 他汀类 内科学 危险系数 PCSK9 急性冠脉综合征 不利影响 安慰剂 心肌梗塞 心脏病学 胆固醇 置信区间 脂蛋白 低密度脂蛋白受体 替代医学 病理 载脂蛋白A1
作者
Rafael Díaz,Qian H Li,Deepak L. Bhatt,Vera Bittner,Marie T. Baccara‐Dinet,Shaun G. Goodman,J. Wouter Jukema,Takeshi Kimura,Alexander Parkhomenko,Robert Pordy,Željko Reiner,Matthew W. Sherwood,Michael Szarek,Hung‐Fat Tse,Harvey D. White,Doron Zahger,Andreas M. Zeiher,Gregory G. Schwartz,Philippe Gabríel Steg
出处
期刊:European Journal of Preventive Cardiology [Oxford University Press]
卷期号:28 (1): 33-43 被引量:43
标识
DOI:10.1177/2047487320941987
摘要

Abstract Aims Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but some patients are statin-intolerant. We examined the effects of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab on the risk of major adverse cardiovascular events according to the intensity of background statin treatment. Methods and results The ODYSSEY OUTCOMES trial compared alirocumab with placebo in 18,924 patients with acute coronary syndrome and dyslipidaemia despite intensive or maximum-tolerated statin treatment (including no statin if intolerance was documented). The primary outcome (major adverse cardiovascular events) comprised coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina. Median follow-up was 2.8 years. Baseline statin treatment was high-intensity (88.8%), low/moderate-intensity (8.7%) or none (2.4%). Median baseline low-density lipoprotein cholesterol was 86, 89 and 139 mg/dL (P < 0.001) in these statin treatment categories, respectively. Alirocumab produced similar relative reductions in low-density lipoprotein cholesterol from baseline across statin treatment subgroups, but the mean absolute reductions differed (52.9, 56.7 and 86.1 mg/dL, respectively; P < 0.001). With placebo, the incidence of major adverse cardiovascular events was highest in the no statin subgroup (10.8%, 10.7% and 26.0% respectively). Alirocumab reduced major adverse cardiovascular events in each statin subgroup (hazard ratio 0.88, 95% confidence interval (CI) 0.80–0.96; 0.68, 0.49–0.94; and 0.65, 0.44–0.97, respectively; Pinteraction = 0.14) with a gradient of absolute risk reduction: 1.25%, 95% CI 0.34–2.16; 3.16%, 0.38–5.94; 7.97%, 0.42–15.51; Pinteraction = 0.106). Conclusions PCSK9 inhibition with alirocumab reduces the relative risk of major adverse cardiovascular events after acute coronary syndrome irrespective of background statin treatment. However, patients on no statin are at high absolute risk for recurrent major adverse cardiovascular events; alirocumab substantially reduces that risk. PCSK9 inhibition may be an important therapeutic strategy for statin-intolerant patients with acute coronary syndrome.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
猫好好完成签到,获得积分10
2秒前
修好世界完成签到,获得积分10
2秒前
Lau完成签到,获得积分10
2秒前
liu完成签到,获得积分10
2秒前
mj完成签到,获得积分10
3秒前
Time完成签到,获得积分10
4秒前
完美世界应助炸药采纳,获得10
4秒前
eleven完成签到,获得积分20
5秒前
6秒前
wyuanhu完成签到,获得积分10
6秒前
朱凌娇完成签到,获得积分10
7秒前
自由的鹏涛完成签到,获得积分20
7秒前
7秒前
大个应助kk采纳,获得30
7秒前
汏流萤完成签到,获得积分10
7秒前
7秒前
大方小松完成签到,获得积分10
8秒前
8秒前
顾矜应助Aminoacid采纳,获得10
8秒前
9秒前
zyyyy完成签到,获得积分10
9秒前
温润如玉坤完成签到,获得积分10
10秒前
十一完成签到,获得积分20
10秒前
cm完成签到,获得积分10
11秒前
一台小钢炮完成签到,获得积分10
12秒前
12秒前
Wguan发布了新的文献求助20
12秒前
英俊的铭应助asdf采纳,获得10
12秒前
我是老大应助123采纳,获得10
13秒前
陨落的繁星完成签到,获得积分10
13秒前
十一发布了新的文献求助10
13秒前
顺科研发布了新的文献求助10
13秒前
李多多完成签到,获得积分10
13秒前
浪浪山第一酷完成签到,获得积分10
14秒前
眼睛大的胡萝卜完成签到 ,获得积分10
14秒前
顺心的飞飞完成签到,获得积分10
14秒前
ymh完成签到,获得积分10
15秒前
dropofwater完成签到,获得积分10
15秒前
文章快快来完成签到,获得积分10
15秒前
ZX612完成签到,获得积分10
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968608
求助须知:如何正确求助?哪些是违规求助? 3513486
关于积分的说明 11168243
捐赠科研通 3248926
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875188
科研通“疑难数据库(出版商)”最低求助积分说明 804676